Why we should not recommend or offer fluvoxamine to COVID-19 patients?
作者信息
Trkulja Vladimir
机构信息
Department of Pharmacology, Zagreb University School of Medicine, Šalata 11, 10000, Zagreb, Croatia.
出版信息
Eur J Clin Pharmacol. 2023 Feb;79(2):321-322. doi: 10.1007/s00228-022-03447-3. Epub 2022 Dec 23.
Abstract
摘要
相似文献
1
Why we should not recommend or offer fluvoxamine to COVID-19 patients?为什么我们不应该向新冠肺炎患者推荐或提供氟伏沙明？
Eur J Clin Pharmacol. 2023 Feb;79(2):321-322. doi: 10.1007/s00228-022-03447-3. Epub 2022 Dec 23.
2
Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe.氟伏沙明预防新冠病毒感染重症化的有效性。
Eur Neuropsychopharmacol. 2023 Feb;67:83-85. doi: 10.1016/j.euroneuro.2022.12.001. Epub 2022 Dec 13.
3
Lack of Benefit of Fluvoxamine for COVID-19.氟伏沙明对新型冠状病毒肺炎无效
JAMA. 2023 Jan 24;329(4):291-292. doi: 10.1001/jama.2022.23954.
4
Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists.氟伏沙明与长期新冠；σ-1受体（S1R）激动剂的新作用
Mol Psychiatry. 2022 Sep;27(9):3562. doi: 10.1038/s41380-022-01545-3. Epub 2022 Apr 6.
5
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
6
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗：当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
7
Considerations before the decision-making including fluvoxamine as a treatment option in guidelines on the management of COVID-19.在做出决策之前的考量，包括将氟伏沙明作为新冠病毒疾病管理指南中的一种治疗选择。
Psychol Med. 2023 Jul;53(9):4296-4297. doi: 10.1017/S0033291722000022. Epub 2022 Feb 16.
8
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.二甲双胍、伊维菌素和氟伏沙明治疗新冠肺炎的试验。回复。
N Engl J Med. 2022 Dec 15;387(24):e65. doi: 10.1056/NEJMc2212542.
9
Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki.对哈尼和恩特扎里 - 马莱基所著《氟伏沙明与长新冠：西格玛 - 1受体（S1R）激动剂的新作用》的评论
Mol Psychiatry. 2022 Sep;27(9):3563-3564. doi: 10.1038/s41380-022-01546-2. Epub 2022 Apr 6.
10
Fluvoxamine for COVID-19?氟伏沙明用于治疗新冠病毒肺炎？
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70.
引用本文的文献
1
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.一项系统评价和荟萃分析，研究了氟伏沙明治疗 COVID-19 病情恶化、死亡和长期 COVID 并发症的剂量和时间疗效。
Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.
2
Overview of the potential use of fluvoxamine for COVID-19 and long COVID.氟伏沙明用于治疗新冠病毒病及新冠后综合征的潜在用途概述。
Discov Ment Health. 2023;3(1):9. doi: 10.1007/s44192-023-00036-3. Epub 2023 Mar 21.
Zotero 插件